Introduction
Next-generation sequencing (NGS) is revolutionizing cancer diagnostics by enabling precise tumor profiling, identifying actionable mutations, and guiding targeted therapies. Widely used in liquid biopsies, NGS helps track cancer progression through circulating tumor DNA (ctDNA) analysis, supporting personalized treatment strategies. Beyond oncology, NGS is pivotal in non-invasive prenatal testing (NIPT) for detecting chromosomal abnormalities and in population genomics, advancing research on genetic diversity and disease susceptibility. It also plays a critical role in infectious disease surveillance, aiding in genomic sequencing of drug-resistant pathogens, vaccine development, and outbreak control.
In Latin America, rising cancer cases and genetic disorders are driving NGS adoption, with countries like Brazil and Mexico investing in genomic diagnostics for precision medicine. As sequencing costs drop, NGS-based personalized healthcare is set to expand, enhancing treatment outcomes globally.
Latin America NGS Market Overview
The Latin America NGS market growth is fueled by the rising adoption of NGS in oncology, infectious disease research, and prenatal diagnostics, driving advancements in precision medicine and genomic healthcare across the region. According to BIS research the market is projected to grow from $268.04 million in 2024 to $597.20 million by 2034, registering a CAGR of 8.34% (2024-2034).
Latin America NGS Market Segmentation
Segmentation 1: based on Offering
Services
Kits and Consumables
Software
Segmentation 2: based on Technology
• Reversible Terminator Sequencing
• Ion Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technology
Segmentation 3: based on Application
• Clinical
• Translational Research
Segmentation 4: based on End-User
• Academic and Research Institutes
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
discovery.
• Government Laboratories
• Other End User
Segmentation 5: based on Country
• Brazil
• Mexico
• Argentina
• Colombia
• Chile
• Costa Rica
• Puerto Rico
• Rest-of-Latin America
Latin America NGS Market Dynamics: Drivers, Challenges and Opportunities
Market Drivers
Rising Disease Burden – Increasing prevalence of cancer, genetic disorders, and infectious diseases is fueling NGS adoption.
Expanding Genomics Infrastructure – Growing investments in local sequencing facilities and strategic partnerships are enhancing accessibility.
Market Challenges
Limited Funding & Reimbursement – High costs and inadequate insurance coverage hinder widespread implementation.
Skill Gaps & Awareness – A shortage of trained specialists and lack of genomic literacy slow adoption.
Market Opportunities
Advancements in AI & Genomic Analytics – AI-driven bioinformatics will streamline sequencing interpretation.
Population Genomics & Personalized Medicine – Large-scale initiatives will drive innovation in precision healthcare.
Latin America NGS Market Future Outlook
The Latin America NGS market is set for rapid expansion, driven by advancements in sequencing technology, rising government investments, and growing clinical applications. Key trends such as AI-powered genomics, population sequencing initiatives, and personalized medicine will shape market growth. As NGS adoption increases, its impact on precision oncology, infectious disease research, and reproductive health will enhance healthcare outcomes across the region.
Explore BIS Research’s tailored Go-to-Market Strategy that help businesses explore and enter emerging markets, promising professional guidance to unlock new opportunities.
